Jason Fontenot

Everything changes — don’t be afraid.

[Stylus Medicine @stylus_medicine]

We are Stylus Medicine - an in vivo genetic medicines company with a bold vision to reimagine and expand the reach of transformative genetic medicines, starting with in vivo CAR-T therapies. Learn more: https://t.co/LOatCanU1X

[Jason Fontenot @jadafo]

Exclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond CRISPR for gene insertion tech - https://t.co/yCKPeslCTn

[Simon Mead @smead2]

Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice | bioRxiv. Impressive work, exciting prospect for human study. https://t.co/ao60rBMp6T

[Jason Fontenot @jadafo]

@f_fauser @SangamoTx Truly impressive work, Frieder! Congrats.

[Jason Fontenot @jadafo]

@SunLab_Official @SchietingerLab @MSKCancerCenter @UW_Immunology Congrats, Andrea. Great photo.

[Jason Fontenot @jadafo]

@jaffeab @chromamedicine @morganlmaeder @CSHL As a start, I would humbly propose an effort eliminate unnecessarily restrictive terms from genome engineering conference titles. Is the international conference on animal flight titled - Chiroptera2023

…and nice work @chromamedicine! Welcome to the future.

[Jason Fontenot @jadafo]

@UrnovFyodor Indeed. Heroic.

[Sangamo Therapeutics @SangamoTx]

Interested in our innovative approach to use iPSCs as a renewable source of allogeneic cells to enable Treg cell therapy manufacturing at scale? Helen Fong, Sangamo's Sr. Scientist joins the @FOCISimmunology Meeting for an oral presentation. Learn more: https://t.co/xshM35Spo0

[Sangamo Therapeutics @SangamoTx]

It’s the last day at #ASGCT23 and we’re excited to wrap up a total of 14 presentations featuring progress across our pipeline. For the latest on all of our presentations, visit our website: https://t.co/DNiOViz1E1

[Sangamo Therapeutics @SangamoTx]

Today we’re showcasing our Viral Delivery Capabilities for Neurology. To discover how our cutting-edge delivery science is progressing, visit the website: https://t.co/DNiOViz1E1 #ASGCT23

[Sangamo Therapeutics @SangamoTx]

Join us at #ASGCT23, where we’ll showcase progress in our pre-clinical programs, including innovations in epigenetic regulation for neurological disorders & our latest advancements in AAV capsid engineering for delivery. See details: https://t.co/bcdaSOpr0a #ZincFinger

[Jason Fontenot @jadafo]

@jaybradner hear, hear!

[Jason Fontenot @jadafo]

@KingOfPathogens @mike_feigin Share?

[Adrian Liston @LabListon]

Using #Tregs no less!

[Simon Mead @smead2]

Zietler presenting amazing data on Prnp knockdown and prion survival benefits by AAV delivered zinc finger by mouse tail vein injection. Wow this is so exciting. Sangamo therapeutics and the irrepressible Minikel Vallabh team 👏 👏 👏 my surprise good news of #prion2022

[Jason Fontenot @jadafo]

Kudos to Bryan Zeitler and the team for the exciting work #prion2022 @SangamoTx

[Jason Fontenot @jadafo]

@LabListon @JExpMed @CarlyEWhyte @singhkailash04 @jldvib Beautiful work, @LabListon.

[Jason Fontenot @jadafo]

Sangamo AAV engineering is firing on all cylinders

[Amy Pooler @amyymelissa]

Sr. Scientist David Ojala’s presentation at #ASGCT22 shared exciting progress of our proprietary approach to engineering novel AAV capsids for improved brain delivery. Proud to be part of a scientific team working so hard to improve care options for patients! @SangamoTx

[Sangamo Therapeutics @SangamoTx]

Today at 4pm ET, join our oral presentation at #ASGCT22 to learn how AAV capsids are designed to provide broad CNS access while minimizing exposure to pre-existing anti-AAV antibodies. More: https://t.co/v62Dl7mVzO #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy

[Amy Pooler @amyymelissa]

Love when our @SangamoTX team has an excuse to get together for food, great science talk and lots of laughs. A fun evening with brilliant colleagues! Now enjoying Day 3 of #ASGCT22.